Regeneron Pharmaceuticals, Inc. (REGN) PT Set at $450.00 by Canaccord Genuity

Henrietta Brewer
February 11, 2017

Roth Capital set a $520.00 price objective on Regeneron Pharmaceuticals and gave the stock a "buy" rating in a research report on Friday, October 28th. Cowen and Company set a $430.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a "hold" rating in a research note on Sunday, November 6th. Fourteen investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock.

Research analysts covering shares of Regeneron Pharmaceuticals, Inc. Insiders have sold 7,125 shares of company stock valued at $2,990,990 over the last three months. The share price has moved forward from its 20 days moving average, trading at a distance of 1.1% and stays 1.33% away from its 50 days moving average. Its products include EYLEA (aflibercept) injection, which is used for the treatment of neovascular age related macular degeneration; ARCALYST (rilonacept), which is used for the treatment of Cryopyrin-Associated Periodic Syndrome, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome; and PRALUENT (alirocumab) Injection for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL- C. Regeneron Pharmaceuticals was founded by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. This was up from $1.10 billion a year ago.

As for as concerns shares volumes, in share of capital Regeneron Pharmaceuticals, Inc. The company reported the earnings of $3.13/Share in the last quarter where the estimated EPS by analysts was $2.71/share. The business had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.30 billion. Regeneron Pharmaceuticals, Inc. got Upgrade on 20-Dec-16 where investment firm Credit Suisse Upgrade the stock from Neutral to Outperform. The firm's quarterly revenue was up 11.7% on a year-over-year basis. This was higher than $258 million, or $2.23 per share, in last year's fourth quarter. Regeneron Pharmaceuticals, Inc. reported better than expected with a surprise EPS of 6.17% or $0.14 during its most recent quarterly earnings.

ILLEGAL ACTIVITY WARNING: This news story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally copied and reposted in violation of USA & global trademark and copyright laws. The shares were bought at an average price of $369.71 per share, with a total value of $32,274,943.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The shares were sold at an average price of $450.00, for a total value of $956,250.00. Following the sale, the director now directly owns 36,500 shares of the company's stock, valued at $15,670,910. The disclosure for this purchase can be found here. During the trading on 02/08/2017, Company's stock ranged from $75.58 to $76.30. State Street Corp increased its stake in Regeneron Pharmaceuticals by 0.5% in the second quarter.

The 52-week high of the share price is 0.14% and 52-week low of the share price is 45.34%.

Regeneron Pharmaceuticals, Inc. closed its last trading session at $353.25 with the gain of 1.91%. Ameriprise Financial Inc. now owns 273,010 shares of the biopharmaceutical company's stock worth $109,756,000 after buying an additional 196,415 shares in the last quarter. Private Advisor Group LLC increased its position in Regeneron Pharmaceuticals by 13.2% in the fourth quarter. Finally, BlackRock Institutional Trust Company N.A. increased its stake in Regeneron Pharmaceuticals by 0.4% in the third quarter.

It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Other reports by iNewsToday